What changed
$ZTS — ADD 📊
Zoetis Inc.
🎯 Q2 2026 | Rev $2B | EPS $1.53 vs $1.62 🔴
💡 Consensus expects stagnant or declining earnings, reflecting the Q1 miss; our variant view is that demand remains resilient and margins will recover, driving positive earnings revisions and multiple expansion from 13.3x toward historical averages (~25x).
📉 Reward/Risk: 2.4:1
🏢 Business Quality: 8/10 - Wide-moat animal health leader with strong recurring revenue, high margins, and essential products, but facing near-term macro and competitive pressures.
📊 Valuation: cheap — current P/E 13.3x vs. 10-year median ~25x; FCF yield likely >5%; EV/EBITDA discount to peers; DCF/reverse DCF supports base-case upside of...
🔮 Catalyst: Next quarterly earnings release and guidance update
💰 Entry: $75.89, stop $68, target $95
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/ZTS0623
Also in play: $CAT $DE $CMI $PCAR $OSK $CMC